PMID- 34598838 OWN - NLM STAT- MEDLINE DCOM- 20220110 LR - 20220110 IS - 1873-460X (Electronic) IS - 1056-8727 (Linking) VI - 35 IP - 12 DP - 2021 Dec TI - Single and joint impact of type 2 diabetes and of congestive heart failure on albuminuria. PG - 108046 LID - S1056-8727(21)00260-9 [pii] LID - 10.1016/j.jdiacomp.2021.108046 [doi] AB - AIMS: Albuminuria is a characteristic feature of diabetic nephropathy, and urine albumin excretion is also increased in patients with congestive heart failure (CHF). However, no data are available on the single and joint associations of type 2 diabetes mellitus (T2DM) and CHF with albuminuria. This issue was addressed in the present study. METHODS: We investigated 4 groups of patients: 180 patients with CHF, of whom 83 had T2DM (CHF+/T2DM+) and 97 did not have diabetes (CHF+/T2DM-) and 223 controls without CHF, of whom 39 had T2DM (CHF-/T2DM+) and 184 did not have diabetes (CHF-/T2DM-). RESULTS: The albumin-creatinine ratio (ACR) was 9.2 [5.7-16.9] mg/g in CHF-/T2DM- patients. Compared to this group it was higher in CHF-/T2DM+ patients (16.1 [7.7-27.8] mg/g; p = 0.004), in CHF+/T2DM- patients (22.0 [9.0-76.8] mg/g; p < 0.001) and in CHF+/T2DM+ patients (66.2 [16.0-177.0] mg/g; p < 0.001), in whom in turn it was higher than in CHF-/T2DM+ (p < 0.001) or in CHF+/T2DM- (p = 0.001) patients. The ACR did not differ significantly between CHF-/T2DM+ and CHF+/T2DM- patients (p = 0.188). In multivariate analysis of covariance, CHF and T2DM proved to be independent predictors of ACR after multivariate adjustment (F = 5.68; p = 0.018 and F = 4.79; p = 0.029, respectively). CONCLUSIONS: We conclude that T2DM and CHF are mutually independent determinants of albuminuria. CI - Copyright (c) 2021. Published by Elsevier Inc. FAU - Saely, Christoph H AU - Saely CH AD - Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Carinagasse 47, AT-6800 Feldkirch, Austria; Private University of the Principality of Liechtenstein, Dorfstrasse 24, FL-9495 Triesen, Liechtenstein; Department of Medicine I, Academic Teaching Hospital Feldkirch, Carinagasse 47, AT-6800 Feldkirch, Austria. FAU - Maechler, Maximilian AU - Maechler M AD - Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Carinagasse 47, AT-6800 Feldkirch, Austria; Private University of the Principality of Liechtenstein, Dorfstrasse 24, FL-9495 Triesen, Liechtenstein; Department of Medicine I, Academic Teaching Hospital Feldkirch, Carinagasse 47, AT-6800 Feldkirch, Austria. FAU - Vonbank, Alexander AU - Vonbank A AD - Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Carinagasse 47, AT-6800 Feldkirch, Austria; Private University of the Principality of Liechtenstein, Dorfstrasse 24, FL-9495 Triesen, Liechtenstein; Department of Medicine I, Academic Teaching Hospital Feldkirch, Carinagasse 47, AT-6800 Feldkirch, Austria. FAU - Sprenger, Lukas AU - Sprenger L AD - Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Carinagasse 47, AT-6800 Feldkirch, Austria; Private University of the Principality of Liechtenstein, Dorfstrasse 24, FL-9495 Triesen, Liechtenstein; Department of Medicine I, Academic Teaching Hospital Feldkirch, Carinagasse 47, AT-6800 Feldkirch, Austria. FAU - Mader, Arthur AU - Mader A AD - Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Carinagasse 47, AT-6800 Feldkirch, Austria; Private University of the Principality of Liechtenstein, Dorfstrasse 24, FL-9495 Triesen, Liechtenstein; Department of Medicine I, Academic Teaching Hospital Feldkirch, Carinagasse 47, AT-6800 Feldkirch, Austria. FAU - Larcher, Barbara AU - Larcher B AD - Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Carinagasse 47, AT-6800 Feldkirch, Austria; Private University of the Principality of Liechtenstein, Dorfstrasse 24, FL-9495 Triesen, Liechtenstein; Department of Medicine I, Academic Teaching Hospital Feldkirch, Carinagasse 47, AT-6800 Feldkirch, Austria. FAU - Zanolin-Purin, Daniela AU - Zanolin-Purin D AD - Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Carinagasse 47, AT-6800 Feldkirch, Austria; Private University of the Principality of Liechtenstein, Dorfstrasse 24, FL-9495 Triesen, Liechtenstein. FAU - Leiherer, Andreas AU - Leiherer A AD - Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Carinagasse 47, AT-6800 Feldkirch, Austria. FAU - Muendlein, Axel AU - Muendlein A AD - Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Carinagasse 47, AT-6800 Feldkirch, Austria. FAU - Drexel, Heinz AU - Drexel H AD - Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT), Carinagasse 47, AT-6800 Feldkirch, Austria; Private University of the Principality of Liechtenstein, Dorfstrasse 24, FL-9495 Triesen, Liechtenstein; Department of Medicine I, Academic Teaching Hospital Feldkirch, Carinagasse 47, AT-6800 Feldkirch, Austria; Drexel University College of Medicine, 2900 W Queen Ln, PA 19129, Philadelphia, USA. Electronic address: heinz.drexel@vivit.at. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210912 PL - United States TA - J Diabetes Complications JT - Journal of diabetes and its complications JID - 9204583 RN - AYI8EX34EU (Creatinine) SB - IM MH - Aged MH - *Albuminuria/etiology MH - Creatinine/urine MH - *Diabetes Mellitus, Type 2/complications MH - *Diabetic Nephropathies/complications MH - Female MH - *Heart Failure/complications MH - Humans MH - Male MH - Middle Aged OTO - NOTNLM OT - Albuminuria OT - Congestive heart failure OT - Type 2 diabetes EDAT- 2021/10/03 06:00 MHDA- 2022/01/11 06:00 CRDT- 2021/10/02 05:29 PHST- 2021/05/12 00:00 [received] PHST- 2021/08/27 00:00 [revised] PHST- 2021/09/07 00:00 [accepted] PHST- 2021/10/03 06:00 [pubmed] PHST- 2022/01/11 06:00 [medline] PHST- 2021/10/02 05:29 [entrez] AID - S1056-8727(21)00260-9 [pii] AID - 10.1016/j.jdiacomp.2021.108046 [doi] PST - ppublish SO - J Diabetes Complications. 2021 Dec;35(12):108046. doi: 10.1016/j.jdiacomp.2021.108046. Epub 2021 Sep 12.